Availability and costs of medicines for the treatment of tuberculosis in Europe

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001187" target="_blank" >RIV/00064190:_____/23:10001187 - isvavai.cz</a>

Result on the web

<a href="https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00394-9/fulltext" target="_blank" >https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00394-9/fulltext</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cmi.2022.07.026" target="_blank" >10.1016/j.cmi.2022.07.026</a>

Result language

angličtina

Original language name

Availability and costs of medicines for the treatment of tuberculosis in Europe

Original language description

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries. Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries. Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were EUR44 (minimum-maximum, EUR15-152), EUR764 (minimum-maximum, EUR542-15152), and EUR8709 (minimum-maximum, EUR7965-11759) in middle-income countries (n = 12) and EUR280 (minimum-maximum, EUR78-1084), EUR29765 (minimum-maximum, EUR11116-40584), and EUR217591 (minimum-maximum, EUR82827-320146) in high-income countries (n = 29), respectively. Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis. (C) 2022 The Author(s)

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30303 - Infectious Diseases

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical Microbiology and Infection

ISSN

1198-743X

e-ISSN

1469-0691

Volume of the periodical

29

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

8

Pages from-to

77-84

UT code for WoS article

000910464500001

EID of the result in the Scopus database

2-s2.0-85138577531